Tag: mscv puro
cMet agonistic antibody prevents acute kidney injury to chronic kidney disease transition by suppressing Smurf1 and activating Smad7
We aimed to research the position of cMet agonistic antibody (cMet Ab) in stopping kidney fibrosis throughout acute kidney damage (AKI) to continual kidney illness (CKD) transition. Moreover, we explored the impact of cMet Ab on TGF-β1/Smad pathway throughout the pathogenesis of kidney fibrosis. A unilateral ischemia-reperfusion damage (UIRI) mouse mannequin was established to induce AKI-to-CKD transition.…
Read More